Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting

Swiss Medical Weekly

Volumn 139, Issue 11-12, 2009, Pages 173-184

  Brändle, Michael ^a   Goodall, G ^b   Erny Albrecht, K M ^b   Erdmann, E ^c   Valentine, W F ^b  

^a CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^b IQVIA   (United States)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Cost effectiveness; Macrovascular events; Pioglitazone; Pro active; Switzerland; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PIOGLITAZONE; PLACEBO;

ADD ON THERAPY; ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; LONG TERM CARE; MACROVASCULAR DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SWITZERLAND; TREATMENT DURATION; TREATMENT OUTCOME; VASCULAR DISEASE;

EID: 64549130858     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Stratton IM, Adler Al, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35):prospective observational study. BMJ. 2000;321(7258):405-12.
2. Diabetes Gessellschaft www.diabetesgesellschaft.ch. Ziele einer umfassenden Behandlung des diabetes Typ 2. 2007.
3. American Association of Clinical Endocrinologists. Medical Guidelines for the Management of Diabetes Mellitus. 2002.
4. International Diabetes Federation. IDF Guidelines for Diabetes Care. http://www d4procom/diabetesguidelines/2005 Available from:URL:http://www.d4pro. com/diabetesguide-lines/
5. National Institute for Clinical Excellence (NICE). UK Type 2 diabetes guidelines (2001). 2007.
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-89.
7. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-93.
8. Vaag AA. Glycemic control and prevention of microvascular and macrovascular disease in the Steno 2 study. Endocr Pract. 2006;12(Suppl l):89-92.
9. Gaede P, Lund-Anderson H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580-91.
10. Charbonnel B, Dormandy J, Erdmann E, Massi-Benedetti M, Skene A. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care. 2004;27(7):1647-53.
11. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28(7):1547-54.
12. The PROactive website, www proactive-results com 2005 Available from: URL:www.proactive-results.com
13. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-89.
14. A desktop guide to Type 2 diabetes mellitus. European Diabetes Policy Group 1999. Diabet Med. 1999;16(9):716-30.
15. Schmitt-Koopman I, Schwenkglenks M, Szucs TD, Spinas G. Direct Medical Costs of Type 2 Diabetes and Its Complications in Switzerland. European J Public Health. 2003;14:3-9.
16. Henzen C, Hodel T, Lehmann B, Mosimann T, Horler U, Joss R. Prevalence and therapy of vascular risk factors in hospitalized type 2 diabetic patients. Schweiz Med Wochenschr. 2000;130(51-52):1979-83.
17. Palmer AJ, Roze S, Valentine WJ, Minshall ME, Foos V, Lurati FM, et al. The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Cost-effectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making. Curr Med Res Opin. 2004;20(8 Suppl):5-26.
18. Palmer AJ, Roze S, Valentine W, Minshall M, Foos V, Lurati F, et al. Validation of the CORE Diabetes Model against Epidemiological and Clinical Studies. Curr Med Res Opin. 2004; 20(Supplement 1):S27-S40.
19. The Mount Hood 4 Modeling Group. Computer modeling of diabets and its complications. Diab Care. 2007;30:1638-46.
20. Valentine WJ, Bottomley J, Palmer AJ, Brandle M, Foos V, Williams R, et al. PROactive 06: Cost effectiveness of pioglitazone in type 2 diabetes in the UK. Diabetic Medicine. 2007;24 (9):982-1002.
21. Leibson CL, O'Brien PC, Atkinson E, Palumbo PJ, Melton LJ, III. Relative contributions of incidence and survival to increasing prevalence of adult-onset diabetes mellitus: a population-based study. Am J Epidemiol. 1997;146(1):12-22.
22. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation. 1997;96(l):44-9.
23. Kannel WB, D'Agostino RB, Silbershatz H, Belanger AJ, Wilson PW, Levy D. Profile for estimating risk of heart failure. Arch Intern Med. 1999;159(11):1197-204.
24. Stevens RJ, Kothari V, Adler Al, Stratton IM, Holman RR. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci. (Lond) 2001;101(6):671-9.
25. Kothari V, Stevens RJ, Adler Al, Stratton IM, Manley SE, Neil HA, et al. UKPDS 60: risk of stroke in type 2 diabetes cstimated by the UK Prospective Diabetes Study risk engine. Stroke. 2002;33(7):1776-81.
26. UKPDS Group. U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249-58.
27. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ. 1997;6 (4):327-40.
28. NICE. National Institute for Clinical Excellence. Guide to the technology appraisal proccess. http://www.nice.org.uk/pdf/ technologyappraisalprocessfinal.pdf (last accessed July 4, 2002). 2001.
29. Swiss Federal Social Insurance Office (BSV). Swiss Federation Office of Social Security. Manual for the standardization of clinical and economic evaluation of medical technology 1998 draft-English. 2007.
30. Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005;14(3):217-30.
31. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). Med Decis Making. 2002;22(4):340-9.
32. Brunner-La Rocca H, Kaiser C, Bcrnheim A, Zellweger MJ, Jeger R, et al. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitäts Trial (BASKET): an 18-month analysis. Lancet. 2007;370:1552-9.
33. Hoey J. Experts disagree over NICE'S approach for assessing drugs. Lancet. 2007;370:643-4.
34. Drummond ME, Bloom BS, Carrin G, I lillman AL, Hutchings HC, Knill-Jones RP, et al. Issues in the cross-national assessment of health technology. Int J Technol Assess Health Care. 1992;8(4):671-82.
35. Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess. 2004;8(49):iii-192.
36. Drummond MF PF. Transferability of economic evaluation results. In: Drummond MF MA, editor. Economic Evaluation in Health Care:Merging Theory with Practice. Oxford University Press; 2007.
37. Gaede P, Valentine WJ, Palmer AJ, Tucker DM, Lammert M, Parving HH, Pedersen O. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. Diabetes Care. 2008;31(8):1510-5.
38. Clarke P, Gray A, Adler A, Stevens R, Raikou M, Cull C, Stratton I, Holman R; UKPDS Group. United Kingdom Prospective Diabetes Study. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia. 2001;44(3):298-304.
39. Comaschi M, Demicheli A, Di Pietro C, Bellatreccia A, Mariz S. COM06 Study Investigators. Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed dose combination of metformin and glibenclamide in patients with type 2 diabetes. Diabetes Technol Ther. 2007;9(4):387-98.
40. Pechere-Bertschi A, Greminger P, Hess L, Philippe J, Ferrari P. Swiss Hypertension and Risk Factor Program (SHARP):cardiovascular risk factors management in patients with type 2 diabetes in Switzerland. Blood Press. 2005;14(6):337-44.
41. Bovier PA, Sebo P, Abetel G, George F, Stalder H. Adherence to recommended standards of diabetes care by Swiss primary care physicians. Swiss Med Wkly. 2007;137(11-12):173-81.
42. Scuffham PA, Chaplin S. A cost-effectiveness analysis of fluvastatin in patients with diabetes after successful percutaneous coronary intervention. Clin Ther. 2005;27(9):1467-77.
43. Palmer AJ, Brandt A, Gozzoli V, Weiss C, Stock H, Wenzel H. Outline of a diabetes disease management model: principles and applications. Diabetes Res Clin Pract. 2000;50(Suppl 3):S47-S56.
44. Aurbach A, Russ W, Battegay E, Bucher HC, Brecht JG, Schadlich PK, et al. Cost-effectiveness of ramipril in patients at high risk for cardiovascular events: a Swiss perspective. Swiss Med Wkly. 2004;134(27-28):399-405.
45. Ghatnekar O. Cost-Effectiveness of treating deep diabetic foot ulcers with Promogran in four different European countries. Journal of wound care 2002;11(2):70.
46. APDRG Suisse. APDRG Suisse. Kostengewichte Version 5.1. 2005.
47. Forum Rettungsdienst Aargau. Tarife Kanton Aargau. Kanton Aargau 2006Available from: URL: www.rettugsdienstaar-gau.ch
48. Tarmed. Tarmed Browser. 2006.
49. Verband der Nierenpatienten Aargau VPN. VPN 2004Avail-able from: URL:www.vpna.ch/haupt-Vintern.htm
50. Schweizerische Unfallversicherungsanstalt (SUVA). Schweizerischer Verband fur Gemeinsehaftsaufgaben der Krankenver-sicherer SVK. Solothurn; 2002. Report No.: Gesehaftsbericht 2001.
51. Palmer AJ, Sendi) PP, Spinas GA. Applying some UK Prospective Diabetes Study results to Switzerland: The cost-effectiveness of intensive glycemic control with metformin versus conventional control in overweight patients with type 2 diabetes. Schweiz Med Wochenschr. 2000;130:1034-40.
52. Ess SM, Schaad UB, Gervaix A, Pinosch S, Szucs TD. Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland. Vaccine. 2003;21 (23):3273-81.
53. Ara A, Brennan A. The cost-effectiveness of sibutramine in non-diabetic obese patients: evidence from four western countries. Obes Rev. 2007, 1-9. 2007.
54. Zurn P, Carrin G, Danthine J-P, Kammerlander R, Kane M. The Economics of Hepatitis B Virus Vaccination: An Analysis of Cost-Effectiveness Results for Switzerland. Dis Manage Health Outcomes. 2007;7(6):331-47.
55. Diel R, Wrighton-Smith P, Zellweger J P. Cost-effectiveness of interferon-gamma release assay testing for the treatment of latent tuberculosis. Eur Respir J. 2007;30(2):321-32.
56. Neeser K, Szucs T, Bulliard JL, Bachmann G, Schramm W. Cost-effectiveness analysis of a quality-controlled mammography screening program from the Swiss statutory health-care perspective: quantitative assessment of the most influential factors. Value Health. 2007;I0(l):42-53.
57. Sendi PP, Bucher HC, Harr T, Craig BA, Schwietert M. Pfluger D, et al. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. AIDS. 1999;13(9):1115-22.
58. Szucs TD, Holm MV, Schwenkglenks M, Zhang Z, Weintraub WS, Burnier M, et al. Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction-an analysis of the EPHESUS study from a Swiss perspective. Cardiovasc Drugs Ther. 2006;20(3):193-204.